In the IFCT-1103 ULTIMATE study, patients with non-squamous NSCLC (the histology mostly affected by KRAS mutations) after one to two previous lines of therapy, including one line of platinum-doublet chemotherapy, were randomized between paclitaxel plus bevacizumab or docetaxel [7]. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.